Drug Profile
Fostroxacitabine bralpamide - Medivir AB
Alternative Names: Fostrox; MIV-818Latest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Medivir AB
- Class Antineoplastics; Bromobenzenes; Dioxolanes; Esters; Nucleotides; Organophosphorus compounds; Pyrimidines; Small molecules
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Liver cancer
Most Recent Events
- 22 Feb 2024 Pharmacokinetics data from a phase I/IIa X trial in Liver cancer released by Medivir AB
- 18 Jan 2024 Adverse events data from phase I/IIa trial for Liver cancer were presented at the ASCO Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 17 Jan 2024 Updated efficacy and safety data from a phase I/IIb trial in Liver cancer presented at the ASCO GI Symposium